What is Identifiability?
Developing models for pharmacokinetic or pharmacodynamic data requires creativity, patience, and hard work. Sometimes that…
Certara2013 年 11 月 18 日
Introduction to Population PK/PD Analysis Using Phoenix NLME
Phoenix NLME provides sophisticated algorithms and powerful and flexible data processing and modeling tools for…
Certara2013 年 11 月 14 日
Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients
The aim of this study was to assess the cardiovascular effects of a new inhaled…
Certara2013 年 11 月 1 日
What is the -2LL or the Log-likelihood Ratio?
Understand the 2LL (Log-likelihood Ratio) and its role in statistical analysis. Explore how it aids…
Certara2013 年 10 月 28 日
Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab
Categorizations of best response observed at week 8 of first-line treatment in two studies of…
Certara2013 年 10 月 22 日
Using Sampling “Windows” for PK Blood Samples
One of the most common questions posed by clinical operations experts when including pharmacokinetic sampling…
Certara2013 年 10 月 15 日
Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers
Ganitumab is an investigational, fully human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor…
Certara2013 年 10 月 1 日
Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters
The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus…
Certara2013 年 9 月 3 日
